Wall Street and Cancer Care

Conference Correspondent

Capital markets fuel the investment and growth of cancer care innovation, and it is difficult to balance the real-world economic impact for delivering this innovation to the marketplace with the real-world realities of the cost, benefits, and value. During the December 11 session of the Association for Value-Based Cancer Care (AVBCC) 10th Annual Summit, a panel of experts shared the Wall Street perspective on the opportunities and challenges ahead for cancer drug developers and healthcare providers.

Jody Hatcher, MBA, Former President of Vizient, who moderated the session, discussed the future of cancer care as a new presidential administration comes into office.

Ipsita Smolinski, MBA, Managing Director of Capitol Street, gave her perspective on the Biden administration, stating that it will be defined by the Georgia races and the distribution of the COVID-19 vaccine. Ms Smolinski said Biden will embrace something like the Most Favored Nation Provision, but with a more scientific view. She does not believe that the Affordable Care Act (ACA) and healthcare plans will be a priority in Biden’s first year in office.

From an investor standpoint, Robert Jones, Global Investment Research at Goldman Sachs, said it is difficult to have a discussion around healthcare without discussing the Supreme Court. Mr Jones thinks it would be challenging for the ACA to be deemed fully unconstitutional.

Lisa Gill, Managing Director of Equity Research at JP Morgan, shared her perspective on the impact of the COVID-19 pandemic on cancer care, noting that there is concern around early detection for cancer. Delays in cancer screenings have led to patients receiving later stage diagnoses, which affect costs and outcomes. One positive aspect of the pandemic, she noted, has been the realization of how much can be done at home via telehealth. However, as the country begins to emerge on the other side of the pandemic, there is an ongoing concern around being able to provide access to the COVID-19 vaccine to underserved populations.

Gain access to these in-depth, expert views on the future of value-based analytics in oncology practices when you register for the AVBCC Summit!

Related Articles